Q-omics provides the consensus-scored BID profile across patient tissues and cancer cell-line models. BID expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, BID is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, BID RNA expression shows 18,732 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, KIRC, and ACC as cancer lineages where BID shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BID — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BID survival associations across molecular data types. BID RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BID RNA expression–survival associations across cancer types. High BID expression shows unfavorable associations in PAAD, UVM, KIRC, ACC and LIHC, but favorable associations in LGG. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for BID RNA expression.
This table summarizes BID tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BID. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BID shows higher tumor expression in KIRC, THCA, HNSC, COAD, BLCA and STAD. The KIRC box plot shows higher BID RNA expression in tumor versus normal tissue (log2 FC = +1.304, t-test p < 0.001).
This table shows molecular features associated with BID in patient tissues and cancer cell lines. In patient samples, BID shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BID RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
